 <h1>Defibrotide Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to defibrotide: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, defibrotide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking defibrotide:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bloody nose</li>
<li>bloody stools</li>
<li>blurred vision</li>
<li>chills</li>
<li>confusion</li>
<li>dizziness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>lightheadedness</li>
<li>rapid, shallow breathing</li>
<li>sweating</li>
<li>unusual tiredness or weakness</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>cough or hoarseness</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>sneezing</li>
<li>sore throat</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>Difficulty with swallowing</li>
<li>hives, itching, or skin rash</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding gums</li>
<li>coughing up blood</li>
<li>headache</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>nosebleeds</li>
<li>paralysis</li>
<li>prolonged bleeding from cuts</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of defibrotide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>nausea</li>
<li>vomiting</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to defibrotide: intravenous solution</i></p><h3>General</h3><p>The most common adverse reactions were hypotension, diarrhea, vomiting, nausea, and epistaxis.  The most common adverse reactions considered to be life-threatening or fatal were hypotension (7%) and pulmonary alveolar hemorrhage (7%).  Hemorrhage events of any type and any grade were reported for 104 (59%) of the patients, and the events were considered life-threatening or fatal in 35 (20%).<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (37%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (24%), vomiting (18%), nausea (16%)</p>
<p><b>Common</b> (1% to 10%): Gastrointestinal hemorrhage</p>
<p><b>Uncommon</b> (0.1% to 1%): Hematemesis, melena, mouth hemorrhage<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (14%)</p>
<p><b>Common</b> (1% to 10%): Pulmonary alveolar hemorrhage, lung infiltration, pneumonia, pulmonary hemorrhage</p>
<p><b>Uncommon</b> (0.1% to 1%): Hemothorax<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Sepsis, graft versus host disease, infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity, anaphylactic reaction<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Hemorrhage intracranial, cerebral hemorrhage</p>
<p><b>Uncommon</b> (0.1% to 1%): Cerebral hematoma<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Coagulopathy, hemorrhage<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Catheter site hemorrhage</p>
<p><b>Uncommon</b> (0.1% to 1%): Injection site hemorrhage<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperuricemia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Hematuria<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Ecchymosis, petechiae, rash, pruritus<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Conjunctival hemorrhage<sup>[Ref]</sup></p><h3>Other</h3><p><b>Uncommon</b> (0.1% to 1%): Pyrexia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Defitelio (defibrotide)." Jazz Pharmaceuticals, Palo Alto, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about defibrotide</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous coagulation modifiers</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Defibrotide Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Defitelio</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hepatic Veno-Occlusive Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to defibrotide: intravenous solution</i></p><h3>General</h3><p>The most common adverse reactions were hypotension, diarrhea, vomiting, nausea, and epistaxis.  The most common adverse reactions considered to be life-threatening or fatal were hypotension (7%) and pulmonary alveolar hemorrhage (7%).  Hemorrhage events of any type and any grade were reported for 104 (59%) of the patients, and the events were considered life-threatening or fatal in 35 (20%).<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypotension (37%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (24%), vomiting (18%), nausea (16%)</p><p><b>Common</b> (1% to 10%): Gastrointestinal hemorrhage</p><p><b>Uncommon</b> (0.1% to 1%): Hematemesis, melena, mouth hemorrhage<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (14%)</p><p><b>Common</b> (1% to 10%): Pulmonary alveolar hemorrhage, lung infiltration, pneumonia, pulmonary hemorrhage</p><p><b>Uncommon</b> (0.1% to 1%): Hemothorax<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Sepsis, graft versus host disease, infection</p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity, anaphylactic reaction<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Hemorrhage intracranial, cerebral hemorrhage</p><p><b>Uncommon</b> (0.1% to 1%): Cerebral hematoma<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Coagulopathy, hemorrhage<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Catheter site hemorrhage</p><p><b>Uncommon</b> (0.1% to 1%): Injection site hemorrhage<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperuricemia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Hematuria<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Ecchymosis, petechiae, rash, pruritus<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Conjunctival hemorrhage<sup>[Ref]</sup></p><h3>Other</h3><p><b>Uncommon</b> (0.1% to 1%): Pyrexia<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Defitelio (defibrotide)." Jazz Pharmaceuticals, Palo Alto, CA. </p><h2>More about defibrotide</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous coagulation modifiers</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Defibrotide Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hepatic Veno-Occlusive Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>